ArticleOncotarget2017
Integrin α5 triggers the metastatic potential in renal cell carcinoma.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- New players in the landscape of renal cell carcinoma bone metastasis and therapeutic opportunities.International journal of cancer · 2025Review
- Increased spatial coupling of integrin and collagen IV in the immunoresistant clear-cell renal-cell carcinoma tumor microenvironment.Genome biology · 2024Article
- Apolipoprotein L1 is a tumor suppressor in clear cell renal cell carcinoma metastasis.Frontiers in oncology · 2024Article
- Increased spatial coupling of integrin and collagen IV in the immunoresistant clear cell renal cell carcinoma tumor microenvironment.bioRxiv : the preprint server for biology · 2023Article
- Targeting integrin α5β1 in urological tumors: opportunities and challenges.Frontiers in oncology · 2023Review
- Article
- ITGA5 is an independent prognostic biomarker and potential therapeutic target for laryngeal squamous cell carcinoma.Journal of clinical laboratory analysis · 2022Article
- CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation.International journal of molecular sciences · 2021Article
- The role of Trop2 in prostate cancer: an oncogene, biomarker, and therapeutic target.American journal of clinical and experimental urology · 2021Article
- [Integrin α5 silencing inhibits proliferation, invasion and metastasis of human liver cancer Bel-7404 cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020Article
- Fibronectin Promotes Cell Growth and Migration in Human Renal Cell Carcinoma Cells.International journal of molecular sciences · 2019Article
- GRASP depletion-mediated Golgi destruction decreases cell adhesion and migration via the reduction of α5β1 integrin.Molecular biology of the cell · 2019Article
- In renal cell carcinoma the PTEN splice variant PTEN-Δ shows similar function as the tumor suppressor PTEN itself.Cell communication and signaling : CCS · 2018Article
- Calcium-sensing receptor (CaSR) promotes development of bone metastasis in renal cell carcinoma.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapy of advanced renal cell carcinoma (RCC) is still a major challenge. To intervene therapeutically a deeper comprehension of the particular steps of metastasis is necessary. In this context membrane bound receptors like integrins play a decisive role. We analyzed the integrin α5 expression in 141 clear cell RCC patients by Western blot. Patients with RCC expressed a significant higher level of integrin α5 in tumor than in normal tissue. The integrin α5 expression correlated with tumor grade, the development of distant metastases within five years after tumor nephrectomy and reduced survival. The RCC cell lines Caki-1 and CCF-RC1, which highly express integrin α5, were treated with fibronectin in combination with or without an inhibiting anti-integrin α5 antibody. Afterwards the migration, adhesion, viability and prominent signaling molecules were analyzed. Both cell lines showed a significant reduced migration potential as well as a decreased adhesion potential to fibronectin after treatment with an integrin α5 blocking antibody. A contribution of the AKT and ERK1/2 signaling pathways could be demonstrated. The results indicate integrin α5 as a potent marker to discriminate patients' tumor prognosis. Consequently the integrin subunit α5 can be considered as a target for individual therapy of advanced RCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.